Home » Newsletters » BioWorld Science

BioWorld Science

April 17, 2001

View Archived Issues

Phase III Oxygent trial shows benefit in reducing and avoiding blood transfusions

Galenica and UAB form research agreement for HSV vaccine

Titan's CeaVac and TriAb studied in combination with radiation therapy for NSCLC

Boehringer Ingelheim and Pfizer to comarket Spiriva for COPD

Second-generation antisense drug shows promise in phase I

Nikken Chemicals investigates dihydropyridines for overcoming MDR

Noncytotoxic taxanes designed as potent MDR reversal agents

Orally active combretastatin A-4 analogues presented at ACS meeting by Abbott researchers

Micro Therapeutics cleared to commence separate pivotal trial of Onyx LES for AVMs

TX-1991, a new DNA-intercalating anticancer agent and radiosensitizer

Abbott identifies antimitotic agents retaining activity in MDR tumors

Millennium and BZL establish agreement for antibody therapies targeting PSMA

Berlex/Schering AG discover highly potent nonamidine factor Xa inhibitor with oral bioavailability

Antitumor and antiangiogenic effects of TNP-470 in models of bladder cancer

Effects of TAK-637 on bladder function in cats detailed at Japanese scientific meeting

Maxim's Ceplene to be included in DITTO-HCV study

MMP inhibitor demonstrates antimetastatic effects following oral administration in murine model

Keryx provides concise report of clinical progress

Vardenafil significantly improves ability to successfully complete intercourse in diverse population

Cyclacel and AstraZeneca form collaboration based on anticancer drug target

The future role of rabeprazole in the treatment of acid-related disorders

New prostaglandin derivatives from Taisho useful for nephropathy and cardiovascular disorders

Aventis presents new inhibitors of coagulation factors

Pfizer's somatostatin antagonists enhance GH secretion

Agents for herpesvirus infections in development at AHP

Recent patent describes Molecumetics' reverse-turn mimetics and their use

Maxia describes series useful in diabetes and hyperproliferative disorders

Broad-spectrum antibacterial activity reported for new FabH inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...